SynthesisProgress in neuro-psychopharmacology & biological psychiatry2015
Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.
Synthesis in Progress in neuro-psychopharmacology & biological psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Systems-level transcriptomic analysis reveals synapse-related gene dysregulation in peripheral leukocytes of MDD patients.Scientific reports · 2026Pooled it
- Antioxidant uric acid in treated and untreated subjects with major depressive disorder: a meta-analysis and meta-regression.European archives of psychiatry and clinical neuroscience · 2018Pooled it
- Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation.Journal of psychopharmacology (Oxford, England) · 2021Trial
- Somatic and sociodemographic predictors of depression outcome among depressed patients with coronary artery disease - a secondary analysis of the SPIRR-CAD study.BMC psychiatry · 2019Trial
- Purinergic system dysregulation and depression: The neuroinflammatory impact of silica nanoparticles.Environmental analysis, health and toxicology · 2025Article
- Discrimination of first-onset patients with bipolar disorder or major depressive disorder using screened biochemical parameters.Annals of general psychiatry · 2025Article
- Potential non-invasive biomarkers of chronic sleep disorders identified by salivary metabolomic profiling among middle-aged Japanese men.Scientific reports · 2025Article
- Global trends of purinergic receptors and depression: A bibliometric analysis from 2003 to 2023.World journal of psychiatry · 2025Article
- Article
- Biomarker signatures as predictors of future impulsivity in schizophrenia: a multi-center study.Frontiers in psychiatry · 2025Article
- Uric Acid: A Biomarker and Pathogenic Factor of Affective Disorders and Neurodegenerative Diseases.Current pharmaceutical design · 2025Review
- Salivary uric acid dynamics are associated with stress response hormones among African Americans in an urban sample.Psychoneuroendocrinology · 2024Article
- Mesenchymal Stem Cells and Purinergic Signaling in Autism Spectrum Disorder: Bridging the Gap between Cell-Based Strategies and Neuro-Immune Modulation.Biomedicines · 2024Review
- Microbial and metabolomic profiles of type 1 diabetes with depression: A case-control study.Journal of diabetes · 2024Article
- P2X7 receptor inhibition alleviates mania-like behavior independently of interleukin-1β.iScience · 2024Article
- Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.Neuropharmacology · 2023Review
- Implication of red meat consumption habits in serum uric acid levels and mood disorders among first-trimester pregnant women.BMC nutrition · 2023Article
- Optimizing multi-domain hematologic biomarkers and clinical features for the differential diagnosis of unipolar depression and bipolar depression.Npj mental health research · 2023Article
- The Wicked Relationship between Depression and Metabolic Syndrome.Clinical neuropsychiatry · 2023Review
- Purinergic signaling: a potential therapeutic target for depression and chronic pain.Purinergic signalling · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Uric acid and purines (such as adenosine) regulate mood, sleep, activity, appetite, cognition, memory, convulsive threshold, social interaction, drive, and impulsivity. A link between purinergic dysfunction and mood disorders was first proposed a century ago. Interestingly, a recent nationwide population-based study showed elevated risk of gout in subjects with bipolar disorder (BD), and a recent meta-analysis and systematic review of placebo-controlled trials of adjuvant purinergic modulators confirmed their benefits in bipolar mania. Uric acid may modulate energy and activity levels, with higher levels associated with higher energy and BD spectrum. Several recent genetic studies suggest that the purinergic system - particularly the modulation of P1 and P2 receptor subtypes - plays a role in mood disorders, lending credence to this model. Nucleotide concentrations can be measured using brain spectroscopy, and ligands for in vivo positron emission tomography (PET) imaging of adenosine (P1) receptors have been developed, thus allowing potential target engagement studies. This review discusses the key role of the purinergic system in the pathophysiology of mood disorders. Focusing on this promising therapeutic target may lead to the development of therapies with antidepressant, mood stabilization, and cognitive effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.